Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
Authors:Mountzios, Giannis (Author)
Remon, J. (Author)
Novello, Silvia (Author)
Blais, N. (Author)
Califano, R. (Author)
Čufer, Tanja (Author)
Dingemans, Anne-Marie C. (Author)
Liu, S. V. (Author)
Peled, N. (Author)
Pennell, N. A. (Author)
Language:English
Tipology:1.03 - Short Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Keywords:non-small cell lung carcinoma, drug therapy, KEYNOTE-024 trial, pemrolizumab, treatment
Year of publishing:2019
Publisher:Elsevier
Source:Velika Britanija
COBISS_ID:2048615281 Link is opened in a new window
UDC:616.2
ISSN on article:1569-8041
OceCobissID:3151892 Link is opened in a new window
DOI:10.1093/annonc/mdz295 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: T. Cufer; Opis vira z dne 15. 1. 2020;
Views:747
Downloads:401
Files:.pdf PDF - Presentation file, download (106,29 KB)
URL URL - Source URL, visit https://academic.oup.com/annonc/article-abstract/30/11/1686/5559466?redirectedFrom=fulltext
 
Journal:Annals of oncology
Elsevier
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:© 2019 THE AUTHORS
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY-NC 4.0, Creative Commons Attribution Non-Commercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:03.09.2019

Archive

niGradiv

Back